TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05129124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
Description: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses at different fittings

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
Description: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses at different fittings

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
Description: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses at different fittings
Study: NCT04808999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: 200 mg IV infusion
Study: NCT06050148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Feacal microbial transplantation (FMT)
Description: Feacal microbial transplantation (FMT)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transplantation (PT)
Description: Transplantation with coloured 0,9% NaCl-solution
Study: NCT06194630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-A3
Description: Intravenous injection of 68Ga-A3 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-A3 will be used to image organs or lesions which expresses ACE2 by PET/CT.
Study: NCT04953754

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: The melatonin group will receive 5mg melatonin nightly

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phillips Actiwatch Spectrum Plus
Description: Both groups will be monitored by the FDA-cleared Actigraph

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phillips Actiwatch Spectrum Plus
Description: Both groups will be monitored by the FDA-cleared Actigraph
Study: NCT05123820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment period A
Description: Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
Study: NCT05129124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
Description: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses at different fittings

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
Description: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses at different fittings

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
Description: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses at different fittings

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
Description: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses at different fittings

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
Description: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses at different fittings

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available Ultra for Astigmatism Contact Lenses
Description: Commercially available Ultra for Astigmatism Contact Lenses at different fittings

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available Ultra for Astigmatism Contact Lenses
Description: Commercially available Ultra for Astigmatism Contact Lenses at different fittings

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available Ultra for Astigmatism Contact Lenses
Description: Commercially available Ultra for Astigmatism Contact Lenses at different fittings

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available Ultra for Astigmatism Contact Lenses
Description: Commercially available Ultra for Astigmatism Contact Lenses at different fittings

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available Ultra for Astigmatism Contact Lenses
Description: Commercially available Ultra for Astigmatism Contact Lenses at different fittings

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available Ultra for Astigmatism Contact Lenses
Description: Commercially available Ultra for Astigmatism Contact Lenses at different fittings
Study: NCT05123820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment period B
Description: ACT-1014-6470 soft capsule for oral administration. Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
Study: NCT05254171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBP-101
Description: small molecule polyamine metabolic inhibitor for subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-paclitaxel
Description: paclitaxel protein-bound particles for injectable suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: paclitaxel protein-bound particles for injectable suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: gemcitabine for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine for injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT06245863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure and Laser
Description: Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 milliwatts (mW) per laser. Vacuum therapy: 60 mm suction cup, pulsed mode (MP9, 50 pulsations per minute) and pressure of -150 at -350 mbar. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Pressure and Laser
Description: Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 mW per laser. Positive Pressure: Massage with rollers. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound and Laser
Description: Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 mW per laser. Ultrasound: 1 megahertz (MHz), continuous mode and 1 milliwatts per square centimeter (mW/cm2). The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Infrared Laser (808 nm), continuous mode, 100 mW. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: Laser: off mode. The placebo treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
Study: NCT06277401

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular training for the knee
Description: The exercise programme includes exercises identified in literature to target muscles around the knee.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-load strength training for the knee
Description: The exercise programme includes exercises identified in literature to target muscles around the knee.
Study: NCT06064357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transverese friction massage and tissue floss technique
Description: Transverse friction massage at Rectus femoris, hip adductors, hamstring, and calf of both lower limbs. TFM on each group of muscle for 30 seconds, 3 sets with 10 seconds rest interval.4 session / week for 6 weeks.~Tissue floss band will be applied on Rectus femoris, hip adductors, calf and hamstring of both lower limbs. Floss band will be wrap around the particular group of muscle from distal to proximal direction with 25 % stretch and 50% overlap and then 10 Reps of rom will be performed the rest interval is 2 mint. 4 sessions / week for 6 weeks.~Conventional physical therapy program included application hot pack for 15 minutes, and Bobath treatment followed by stretching of calf (10 repetitions with at least 8 seconds hold) 4 times / week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transverese friction massage and tissue floss technique
Description: Transverse friction massage at Rectus femoris, hip adductors, hamstring, and calf of both lower limbs. TFM on each group of muscle for 30 seconds, 3 sets with 10 seconds rest interval.4 session / week for 6 weeks.~Tissue floss band will be applied on Rectus femoris, hip adductors, calf and hamstring of both lower limbs. Floss band will be wrap around the particular group of muscle from distal to proximal direction with 25 % stretch and 50% overlap and then 10 Reps of rom will be performed the rest interval is 2 mint. 4 sessions / week for 6 weeks.~Conventional physical therapy program included application hot pack for 15 minutes, and Bobath treatment followed by stretching of calf (10 repetitions with at least 8 seconds hold) 4 times / week for 6 weeks.
Study: NCT06333717

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole grain bread
Description: Consumption of high-fibre bread as a dietary supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control bread
Description: Consumption of control bread as a dietary supplementation
Study: NCT06167525

Intervention type: DEVICE
Group type: OTHER
Intervention: Real-time feedback through the device. Bio-feedback signals will be given once deviated from a neutral posture for >1 minute. Response of surgeons to bio-feedback signals will be recorded
Description: During the first stage of the study the device will be set to record cervical spine positioning without bio-feedback signals. This will be used to record duration of time surgeons held maladaptation postures.~The second stage will involve real-time feedback through the device. For surgeons who consent, bio-feedback signals will be given once deviated from a neutral posture for \>1 minute. Response of surgeons to bio-feedback signals will also be recorded.~The Neck Disability index score will be used to assess for neck pain and the functional implications in relation to reported neck pain. This will be completed following study completion.
Study: NCT05500664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lavender Oil
Description: three drops of the designated lavender will be placed on a 2-inch by 2-inch impermeable, backed gauze pad and patient was asked to inhale deeply for 5 minutes
Study: NCT04576741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bMBI shorter more frequent practice
Description: This is a 12-week online mindfulness-based course blended with therapist support via video link using shorter, more frequent practice than standard Mindfulness-Based Cognitive Therapy (2x15-minutes/day).
Study: NCT06363630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golcadomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golcadomide
Description: Specified dose on specified days
Study: NCT04959383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low complexity Exergaming group
Description: This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept low for this group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate complexity Exergaming group
Description: This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept moderate for this group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High complexity Exergaming group
Description: This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept high for this group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. This group will receive exergame balance training on Wii fit. Participants in this group will play Soccer Heading, Ski Slalom, Ski Jump, Table Tilt, Tightrope Walk, Balance Bubble, Penguin Slide and Snowboard Slalom game.
Study: NCT05813938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LabTest Checker
Description: A set of blood laboratory tests is ordered. Test results are recorded in the LabTest Checker. LabTest Checker's diagnostic engine automatically generates a personalized questionnaire that is filled out by the patient. After obtaining all necessary information, including the patient's chronic diseases, medications taken, and symptoms, the tool presents an interpretation of test results.
Study: NCT04837027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Aerobic training on stationary bike 5x a week for 30 minutes a day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance training
Description: Training 5x a week for 30 minutes. Standard of care
Study: NCT06586151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendent Health
Description: Gender-inclusive HIV prevention program: Text messaging-based program that lasts 5 months. Content includes information, motivation and behavioral skills about how to prevent HIV, as well as information about healthy and unhealthy romantic relationships, and navigating issues related to one\&#39;s gender.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Text Messaging with Information
Description: Text messaging-based program that lasts 5 months. Content includes information about HIV prevention and aspects of a healthy adolescent lifestyle (e.g., self-esteem).
Study: NCT06601621

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: electroacupuncture+ self-acupressure
Description: Participants will receive two electroacupuncture treatments within the first week of each treatment cycle. The acupuncturist inserts the needle into the point and manipulates the needle until the feeling of deqi; is achieved and reported by the participant. The electrical stimulation will be administered at a sustained frequency of 2/10Hz for 30 minutes. self-acupressure: In weeks 2 and 3 of each treatment cycle, participants performed true self-administered acupressure, pressing each acupoint with their thumb to achieve deqi; for three minutes.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: sham electroacupuncture + sham self-acupressure
Description: Sham electroacupuncture: The sham electroacupuncture shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive acupuncture treatment without electrical stimulation same the intervention group. And avoid deqi; sensation. Sham self-acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of deqi.
Study: NCT04686227

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D Ultrasound
Description: Newly married women between the ages of 18-40 will be evaluated by 3D ultrasonography about the uterine morphology

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D Ultrasound
Description: Newly married women between the ages of 18-40 will be evaluated by 3D ultrasonography about the uterine morphology
Study: NCT05481697

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GRAIL Galleri
Description: A blood test that aims to detect cancers earlier by looking for abnormal DNA shed from cancer cells into the blood.
Study: NCT06589986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7790121
Description: RO7790121 will be administered as IV infusion. RO7790121 will be administered as SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching IV RO7790121. Placebo matching SC RO7790121.
Study: NCT06614660

Intervention type: OTHER
Intervention: Metabolism genomics and imaging genomics
Description: Pre-operative imaging images of the patient were collected prior to surgery, and 2 ml of the patient\&#39;s blood specimen was collected to collect metabolism genomics and imaging genomics.
Study: NCT06480864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab Injection
Description: Adebrelimab injection (1200mg) will be administered by intravenous infusion during the induction phase and maintenance phase on day 1 in a 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: Apatinib mesylate tablets (250 mg) will be administered orally in a 3-week treatment cycle, once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC 4-5mg/mL/min) intravenous infusion will be administered during the induction phase on day 1 in a 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (75mg/m2) intravenous infusion will be administered during the induction phase on day 1 in a 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide(100mg/m2) intravenous infusion will be administered during the induction phase from day 1 to 3 in a 3-week treatment cycle.
Study: NCT05255913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanosilver
Description: preventive material for arresting caries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver diamine fluoride
Description: preventive material for arresting caries
Study: NCT06552507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duroplasty
Description: The investigators open the dura from midline and repaired with fish mouth for dura augmentation
Study: NCT05900011

Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaire
Description: Measurement of the quality of life of patients with eosinophilic esophagitis by the PedsQL questionnaire eosinophilic esophagitis module
Study: NCT06154031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyad learning
Description: All participants will perform a gamified exercise using a dyad learning protocol. This means that all participants will practice the gamified exercise in pairs (dyads), for 60 minutes on two consecutive days.
Study: NCT04296526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Prescription
Description: To prescribe exercise programs that can be easily applied at home/dormitory/living place for students.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Prescription
Description: To prescribe exercise programs that can be easily applied at home/dormitory/living place for students.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Prescription
Description: To prescribe exercise programs that can be easily applied at home/dormitory/living place for students.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Education
Description: To organize sessions for how to proper exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Education
Description: To organize sessions for how to proper exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Education
Description: To organize sessions for how to proper exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: Supports such as peer influence or reminder phone messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: Supports such as peer influence or reminder phone messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: Supports such as peer influence or reminder phone messages
Study: NCT05524870

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: Movement with mobilization plus exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: Movement with mobilization plus exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mobilization
Description: Movement with mobilization plus exercise
Study: NCT05515822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Hydrochloride
Description: The doses were calculated according to the ideal body weight. Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dezocine
Description: Dezocine was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine and Oxycodone
Description: Esketamine was administered 5min before skin incision, and Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.